Taberbovcamine C






Names

    • Taberbovcamine C

Attributes

  • Canonical SMILES

    CC[C@]1([C@]2([H])N3CCC4=C2N([C@@](C(OC)=O)(C1)O)C5=C4C=C(OC)C(OC)=C5)C=CC3=O

  • InChI

    InChI=1S/C23H26N2O6/c1-5-22-8-6-18(26)24-9-7-13-14-10-16(29-2)17(30-3)11-15(14)25(19(13)20(22)24)23(28,12-22)21(27)31-4/h6,8,10-11,20,28H,5,7,9,12H2,1-4H3/t20-,22+,23+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 90.23000000000002
  • #RotBonds: 4
  • MW: 426.46900000000016
  • HBD: 1
  • HBA: 7
  • logP: 2.2723000000000004
  • Chemical Formula: C23H26N2O6


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. bovina China, Vietnam 3036760 Cai20150423

External Databases


References

  • Vincan- and eburnan-type alkaloids from Tabernaemontana bovina and their hypoglycemic activity. Phytochemistry, 2021 (PMID 34218044).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Hypoglycemic

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.81
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.82
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -1.78
    Distribution Blood-Brain Barrier (Central Nervous System) -2.98
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.83
    Plasma Protein Binding 58.99
    Steady State Volume of Distribution 0.87
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 5.28
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor 0.3
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.13
    Liver Injury II Toxic
    hERG Blockers Safe
    Daphnia Maga 5.38
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Toxic
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -76.79
    Rat (Acute) 2.59
    Rat (Chronic Oral) 1.98
    Fathead Minnow 4.31
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Toxic
    SR-ARE Toxic
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Toxic
    General Properties Boiling Point 483.59
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 2.17
    Log(P) 1.55
    Log S -2.34
    Log(Vapor Pressure) -8.54
    Melting Point 231.55
    pKa Acid 8.47
    pKa Basic 5.47